Filter Results:
(2)
Show Results For
- All HBS Web (8)
- Faculty Publications (1)
Show Results For
- All HBS Web (8)
- Faculty Publications (1)
Page 1 of 2
Results
Sort by
- 2024
- Working Paper
Chimeric Antigen Receptor T-Cell Therapy—Living Drugs: Case Histories of Transformational Advances
By: Amar Bhidé and Srikant M. Datar
In 2017, the US Food and Drug Administration (FDA) approved an immunotherapeutic treatment, called CAR-T therapy, for two kinds of blood cancers—acute leukemia (ALL) and a lymphoma. We describe 1) how CAR-T works, 2) the foundational advances and discoveries, 3) the... View Details
Keywords: Immunotherapy; Health Care and Treatment; Innovation and Invention; Research and Development; Governing Rules, Regulations, and Reforms
Bhidé, Amar, and Srikant M. Datar. "Chimeric Antigen Receptor T-Cell Therapy—Living Drugs: Case Histories of Transformational Advances." Harvard Business School Working Paper, No. 21-035, August 2020. (Revised May 2024.)
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
therapies has become a reality, as have immunotherapies that induce or suppress a body’s immune response to treat disease. Yet, this relatively swift progress has not been fast enough for millions of other patients who still lack... View Details